102804-77-3

Basic information

• Product Name: 4-Desmethoxypropoxyl-4-methoxy Rabeprazole
• Synonyms: Rabeprazole EP Impurity E;2-[[(4-Methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole;4-Desmethoxypropoxyl-4-methoxy Rabeprazole;Rabeprazole 4-Methoxy IMpurity;4-Methoxy Rabeprazole;Rabeprazole 4-Methoxy Analog;RaBeprazole impurity 9
• CAS NO: 102804-77-3
• Molecular Formula: C₁₅H₁₅N₃O₂S
• Molecular Weight: 300.35556
• Product Categories: Various Metabolites and Impurities;Metabolites & Impurities;Aromatics;Heterocycles;Impurities;Sulfur & Selenium Compounds
• Mol File: 102804-77-3.mol
• Article Data: 1

Chemical Properties

• Melting Point: 141-143°C (dec.)
• Boiling Point: 571.7±60.0 °C(Predicted)
• Appearance: /
• Density: 1.40±0.1 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 9.58±0.10(Predicted)
• CAS DataBase Reference: 4-Desmethoxypropoxyl-4-methoxy Rabeprazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Desmethoxypropoxyl-4-methoxy Rabeprazole(102804-77-3)
• EPA Substance Registry System: 4-Desmethoxypropoxyl-4-methoxy Rabeprazole(102804-77-3)

Safety Data

• Hazardous Substances Data: 102804-77-3(Hazardous Substances Data)

Usage

Chemical Properties

Tan Solid

Uses

A process impurity of Rabeprazole (R070500).

Upstream product

• 86604-74-2 2-chloromethyl-4-methoxy-3-methylpyridine hydrochloride 
• 102625-98-9 2-acetoxymethyl-4-methoxy-3-methylpyridine 
• 102625-96-7 4-methoxy-2,3-dimethylpyridine 1-oxide 
• 86604-77-5 2-hydroxymethyl-4-methoxy-3-methylpyridine 
• 59886-90-7 4-chloro-2,3-dimethylpyridine-N-oxide 
• 37699-43-7 2,3-dimethyl-4-nitropyridine N-oxide 
• 102804-82-0 2-[[(4-methoxy-3-methylpyridin-2-yl)methyl]mercapto]-1H-benzimidazole 
• 1589-49-7 methoxypropanol 
• 134469-07-1 Benzimidazol-2-thiol 

Relevant articles and documents

Identification and synthesis of potential impurities of rabeprazole sodium

Rabeprazole sodium (1, Achiphex) is a gastric proton pump inhibitor. It causes dose-dependent inhibition of acid secretion and is useful as an anti-ulcer agent. In the process for the preparation of 1, two potential unknown impurities were identified in HPLC at levels ranging from 0.05-0.8%. Based on mass spectral data vide LC-MS, the two impurities were characterized as 2-{[(4-chloro-3-methyl-2-pyridinyl) methyl] sulfinyl}-1H-bezimidazole (2, chloro analogue of rabeprazole) and 2-[{(4-methoxy-3-methyl-2-pyridinyl)methyl} sulfinyl]-1H-benzimidazole (3, methoxy analogue of rabeprazole). The structures were unambiguously established by independently synthesizing them and co-injecting in HPLC. To our knowledge, the compounds 2 and 3 have not been reported as process impurities elsewhere.